Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

• Published in: International journal of cancer Vol. 132; no. 11; pp. 2471 - 2478
• Main Authors: Nars, Mariana S., Kaneno, Ramon
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2013; Wiley-Blackwell; Wiley Subscription Services, Inc
• Subjects: Animals; Antineoplastic Agents - administration & dosage; Biological and medical sciences; Cancer; Chemotherapy; Combined Modality Therapy; dendritic cells; Humans; Immunologic Factors - administration & dosage; Immunotherapy; Medical research; Medical sciences; metronomic; Neoplasms - immunology; Neoplasms - therapy; Treg; Tumors; vaccine; Dendritic cell; Immunomodulation; Low dose; Treg; Vaccine; Posology; Immunoprophylaxis; Chemotherapy; Perspective; metronomic; Treatment; Cancerology; dendritic cells; Antigen presenting cell; Immunotherapy
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.27801

Given that cancer is one of the main causes of death worldwide, many efforts have been directed toward discovering new treatments and approaches to cure or control this group of diseases. Chemotherapy is the main treatment for cancer; however, a conventional schedule based on maximum tolerated dose (MTD) shows several side effects and frequently allows the development of drug resistance. On the other side, low dose chemotherapy involves antiangiogenic and immunomodulatory processes that help host to fight against tumor cells, with lower grade of side effects. In this review, we present evidence that metronomic chemotherapy, based on the frequent administration of low or intermediate doses of chemotherapeutics, can be better than or as efficient as MTD. Finally, we present some data indicating that noncytotoxic concentrations of antineoplastic agents are able to both up‐regulate the immune system and increase the susceptibility of tumor cells to cytotoxic T lymphocytes. Taken together, data from the literature provides us with sufficient evidence that low concentrations of selected chemotherapeutic agents, rather than conventional high doses, should be evaluated in combination with immunotherapy.